{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=107",
    "query": {
      "condition": "Patient",
      "page": 107
    },
    "page_size": 10
  },
  "pagination": {
    "page": 107,
    "page_size": 10,
    "total_count": 54995,
    "total_pages": 5500,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=108&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=106&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:56:25.577Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05338151",
      "title": "Promoting Alcohol Treatment Engagement Post-hospitalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Brief Negotiated Interview (BNI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BNI+facilitated provision of MAUD",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 417,
      "start_date": "2022-09-13",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05338151"
    },
    {
      "nct_id": "NCT00868751",
      "title": "Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Arthritis, Juvenile Rheumatoid",
        "Still's Disease, Juvenile Onset"
      ],
      "interventions": [
        {
          "name": "tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-03",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868751"
    },
    {
      "nct_id": "NCT06551129",
      "title": "Real-world Patient Reported Outcomes Among Patients Treated With Camzyos",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obstructive Hypertrophic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Mavacamten",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2024-05-10",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06551129"
    },
    {
      "nct_id": "NCT00517829",
      "title": "Docetaxel+Oxali+/-Cetux Met Gastric/GEJ",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer Adenocarcinoma Metastatic"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Oncology Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2007-07",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00517829"
    },
    {
      "nct_id": "NCT06750731",
      "title": "Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Disease (IBD)",
        "Crohn's Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Tappt",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mercy Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-05-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 6,
      "location_summary": "New Orleans, Louisiana • Chevy Chase, Maryland • New York, New York + 3 more",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06750731"
    },
    {
      "nct_id": "NCT01788202",
      "title": "Patients With Positive Urine Cocaine Metabolites Undergoing General Anesthesia",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Emergent Surgery"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 2,
      "start_date": "2013-01",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-09-08",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01788202"
    },
    {
      "nct_id": "NCT04977453",
      "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Cervical Cancer",
        "Urothelial Carcinoma",
        "Clear Cell Renal Cell Cancer (ccRCC)",
        "Squamous Cell Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "GI-101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "GI-101A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GI Innovation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2021-08-02",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 3,
      "location_summary": "New York, New York • Huntersville, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977453"
    },
    {
      "nct_id": "NCT00266253",
      "title": "A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "GK Activator (2)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 220,
      "start_date": "2005-11",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00266253"
    },
    {
      "nct_id": "NCT01503853",
      "title": "Discussing Costs in the Doctor-Patient Encounter",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Illness",
        "Financial Burden"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2011-04-16",
      "completion_date": "2016-09-16",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01503853"
    },
    {
      "nct_id": "NCT00739453",
      "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "OSI-906",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2008-10-23",
      "completion_date": "2012-03-03",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-11-15T09:56:25.577Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739453"
    }
  ]
}